FLEMMING ORNSKOV, M.D., M.P.H.

Corporate Board Profile

Tech Score: 0/100

WATERS CORP /DE/

Filing Date	Source Excerpt
2019-04-04	Dr. Ornskov, 61, has served as a Director of the Company since June 2017. From January 8, 2019 to March 31, 2019, Dr. Ornskov served as an advisor to the CEO of Takeda Pharmaceutical Company Ltd. He served as the Chief Executive Officer Designate, as well as Board Member of Shire Plc from January 2, 2013, and as Chief Executive Officer from April 30, 2013 to January 8, 2019. From 2010 to 2012, he served as the Chief Marketing Officer and Global Head of Strategic Marketing for General & Specialty Medicine at Bayer AG. From 2008 to 2010, he served as Global President of Pharmaceuticals and OTC at Bausch & Lomb, Inc. From 2006 to 2008, he also served as the Chairman and later as President and Chief Executive Officer of Life-Cycle Pharma A/S. From 2005 to 2006, he served as President and Chief Executive Officer of Ikaria, Inc. In his pharmaceutical career, he had roles of increasing responsibility at Merck & Co. Inc. and Novartis AG.
2020-04-02	Chief Executive Officer of Galderma, a pharmaceutical company (October 2019 to present) Advisor to the CEO of Takeda Pharmaceutical Company Ltd. (January 2019 to March 2019) Chief Executive Officer of Shire plc (April 2013 to January 2019); Chief Executive Officer Designate (January 2013 to April 2013); Board Member (January 2013 to January 2019) Chief Marketing Officer and Global Head of Strategic Marketing for General & Specialty Medicine at Bayer AG (2010 to 2012) Global President of Pharmaceuticals and OTC at Bausch & Lomb, Inc. (2008 to 2010) Chairman and later as President and Chief Executive Officer of Life-Cycle Pharma A/S (2006 to 2008) President and Chief Executive Officer of Ikaria, Inc. (2005 to 2006) Held roles of increasing responsibility at Merck & Co. Inc. and Novartis AG

Filing Date

Source Excerpt

2019-04-04

Dr. Ornskov, 61, has served as a Director of the Company since June 2017. From January 8, 2019 to March 31, 2019, Dr. Ornskov served as an advisor to the CEO of Takeda Pharmaceutical Company Ltd. He served as the Chief Executive Officer Designate, as well as Board Member of Shire Plc from January 2, 2013, and as Chief Executive Officer from April 30, 2013 to January 8, 2019. From 2010 to 2012, he served as the Chief Marketing Officer and Global Head of Strategic Marketing for General & Specialty Medicine at Bayer AG. From 2008 to 2010, he served as Global President of Pharmaceuticals and OTC at Bausch & Lomb, Inc. From 2006 to 2008, he also served as the Chairman and later as President and Chief Executive Officer of Life-Cycle Pharma A/S. From 2005 to 2006, he served as President and Chief Executive Officer of Ikaria, Inc. In his pharmaceutical career, he had roles of increasing responsibility at Merck & Co. Inc. and Novartis AG.

2020-04-02

Chief Executive Officer of Galderma, a pharmaceutical company (October 2019 to present) Advisor to the CEO of Takeda Pharmaceutical Company Ltd. (January 2019 to March 2019) Chief Executive Officer of Shire plc (April 2013 to January 2019); Chief Executive Officer Designate (January 2013 to April 2013); Board Member (January 2013 to January 2019) Chief Marketing Officer and Global Head of Strategic Marketing for General & Specialty Medicine at Bayer AG (2010 to 2012) Global President of Pharmaceuticals and OTC at Bausch & Lomb, Inc. (2008 to 2010) Chairman and later as President and Chief Executive Officer of Life-Cycle Pharma A/S (2006 to 2008) President and Chief Executive Officer of Ikaria, Inc. (2005 to 2006) Held roles of increasing responsibility at Merck & Co. Inc. and Novartis AG

Data sourced from SEC filings. Last updated: 2025-10-12